Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($) |
Common Stock [Member] |
Preferred Stock [Member] |
Additional Paid-In Capital [Member] |
Subscription Receivable [Member] |
Accumulated Deficit [Member] |
Total |
---|---|---|---|---|---|---|
Balance at Dec. 31, 2017 | $ 3,527 | $ 4,228,723 | $ (3,859,086) | $ 373,164 | ||
Balance, shares at Dec. 31, 2017 | 35,272,626 | |||||
Recognize the fair value of the license acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet | 8,000,000 | 8,000,000 | ||||
Net loss | (1,096,798) | (1,096,798) | ||||
Balance at Mar. 31, 2018 | $ 3,527 | 12,228,723 | (4,955,884) | 7,276,366 | ||
Balance, shares at Mar. 31, 2018 | 35,272,626 | |||||
Balance at Dec. 31, 2018 | $ 3,867 | 19,121,285 | $ (1,800,000) | (7,624,134) | 9,701,018 | |
Balance, shares at Dec. 31, 2018 | 38,674,265 | |||||
Stock-based compensation | 58,559 | 58,559 | ||||
Payments made directly by investor for clinical trial costs | 115,000 | 115,000 | ||||
Net loss | (750,832) | (750,832) | ||||
Balance at Mar. 31, 2019 | $ 3,867 | $ 19,179,844 | $ (1,685,000) | $ (8,374,966) | $ 9,123,745 | |
Balance, shares at Mar. 31, 2019 | 38,674,265 |
X | ||||||||||
- Definition Payments made directly by investor for clinical trial costs. No definition available.
|
X | ||||||||||
- Definition Amount of other increase (decrease) in additional paid in capital (APIC). No definition available.
|
X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of shares issued which are neither cancelled nor held in the treasury. No definition available.
|
X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|